Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Melbourne scientists have shown for the first time how a “revolutionary” blood cancer treatment could be tweaked to also cure ...